CN110152021A - A kind of medicament carrier system and preparation method thereof having target administration ability in cancer cell - Google Patents

A kind of medicament carrier system and preparation method thereof having target administration ability in cancer cell Download PDF

Info

Publication number
CN110152021A
CN110152021A CN201910563157.8A CN201910563157A CN110152021A CN 110152021 A CN110152021 A CN 110152021A CN 201910563157 A CN201910563157 A CN 201910563157A CN 110152021 A CN110152021 A CN 110152021A
Authority
CN
China
Prior art keywords
pll
dots
prussian blue
carrier system
cancer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910563157.8A
Other languages
Chinese (zh)
Other versions
CN110152021B (en
Inventor
李草
陈重银
万立辉
陈辉
段军林
徐翔宇
卢金博
罗毕矗
江兵兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei University
Original Assignee
Hubei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubei University filed Critical Hubei University
Priority to CN201910563157.8A priority Critical patent/CN110152021B/en
Publication of CN110152021A publication Critical patent/CN110152021A/en
Application granted granted Critical
Publication of CN110152021B publication Critical patent/CN110152021B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

The invention discloses a kind of Drug Carrier Systems, be modified with carbon quantum dot and beta cyclodextrin it is Prussian blue for matrix, after being grafted in conjunction with polylysine with the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of NO donor 5-, then obtained from modified with folic acid.Medicament carrier system provided by the invention can realize effective enrichment in tumor locus by folate-targeted and tumor locus EPR effect, and under near-infrared laser irradiation, prussian blue nano particle can pass through excellent photothermal conversion efficiency ablated tumor cell.Simultaneously, the medicament carrier system can control nitric oxide production release under the illumination of 400nm wavelength, enhance nanoparticle in the enrichment of tumor locus so as to improve EPR effect, NO can inhibit tumour growth with inducing apoptosis of tumour cell, reverse multidrug resistance etc. simultaneously.

Description

It is a kind of to have the medicament carrier system of target administration ability and its preparation in cancer cell Method
Technical field
The invention belongs to pharmaceutical carrier fields, and in particular to a kind of pharmaceutical carrier for having target administration ability in cancer cell System and preparation method thereof.
Background technique
In recent years, with the deterioration of natural environment, the disease incidence of cancer is higher and higher.Traditional anti-cancer therapies packet It includes: operative treatment, chemotherapy and radiation.Although can extend the life of patient to a certain extent, these therapeutic modalities are general The disadvantages of store-through is larger in toxic side effect, damages normal tissue and larger wound, to limit its therapeutic effect to tumour. Therefore, new therapeutic modality is developed to get growing concern for.
Currently, chemotherapy is antitumor primary treatment scheme, but challenge of the chemotherapy by multidrug resistance (MDR), this is very The curative effect of chemotherapy is limited in big degree.And often using high dose and increase administration frequency.But high dose and increase administration Frequency will not significantly improve therapeutic effect, often bring instead to vitals (heart, liver and kidney) serious bad Side effect, it is possible to further deteriorate drug resistance.Compared with traditional small-molecule drug chemotherapy of tumors, since near-infrared irradiation is set It sets controllably, such as irradiation time, light source position, power output, so photo-thermal therapy (PTT) photodynamic therapy (PDT) is with low The characteristics of poison, high specific.
Photo-thermal therapy (PTT) is a kind of new tumor therapeuticing method, has Noninvasive and space-time controllability.Photo-thermal therapy Basic principle be: optothermal material by EPR effect tumor locus assemble, then under near infrared light, make tumour office Portion's temperature is increased more than 42 DEG C, so that tumor cell damage be made even to be eliminated tumour cell, achievees the purpose that treating cancer.Pu Lu Scholar's indigo plant (PB) due to special ion exchange, absorption and mechanical trapping characteristic, food and drug administration (FDA) in Antidote of the approval lead in 2003 as thallium and caesium inner radiation contact scar, shows its good biological safety and biofacies Capacitive.The nm near-infrared absorbing material (such as polypyrrole nanoparticle, gold nanoparticle, CuS nanoparticle) emerging with other It compares, PB nanoparticle has good biocompatibility, higher photothermal conversion efficiency, photostability and easily-controllable size etc. excellent Point.
Photodynamic therapy (PDT) is as a kind of emerging treatment means, since its invasion is small, Small side effects, drug resistance The advantages that small, receives more and more attention in oncotherapy.Current optical dynamic therapy multi-pass crosses active oxygen (ROS) induction Apoptosis, necrosis and disorganization.Unfortunately, angiogenesis abnormal in solid tumor and thrombosis will lead to oxygen supply with Oxygen consumption is unbalance, causes high-caliber anoxic.The low-oxygen environment of tumor tissues may be decreased the concentration of effective oxygen in PDT, limit ROS Generation.The generation of NO then needs not rely on the oxygen in tumor tissues, and the vasodilation that can be mediated by NO, mitigates swollen The anoxic at tumor position.
Summary of the invention
The technical problem to be solved by the present invention is to provide a kind of drug load in view of the deficiency of the prior art System system, compared to traditional load drug carrier, which has target administration ability in more efficient cancer cell, can effectively mention High utilization ratio of drug simultaneously reduces its toxic side effect.
The present invention be solve the problems, such as it is set forth above used by technical solution are as follows:
Medicament carrier system provided by the present invention, be modified with carbon quantum dot and beta cyclodextrin it is Prussian blue for matrix, After being grafted in conjunction with polylysine with the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of NO donor 5-, then obtained from modified with folic acid.
Said medicine carrier system, preparation method mainly include the following steps:
Step 1 synthesizes the Prussian blue (PB-CD-NH of beta cyclodextrin and 2-aminoethyl disulfide dihydrochloride modification2)
Prussian blue (PB) is dispersed in the buffer solution that pH is 5-6, then under conditions of ice-water bath, 1- is added (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride (EDC) and n-hydroxysuccinimide react 20-30 hours;So Afterwards, it is subsequently added into beta cyclodextrin (EDA- β-CD) and 2-aminoethyl disulfide dihydrochloride reacts at room temperature 20-30 hours, separate and clean solid production Object obtains PB-CD-NH2
Step 2, Prussian blue (PB-C-dots-CD) of synthesis carbon quantum dot modification
Carbon quantum dot (C-dots) is dispersed in the buffer solution that pH is 5-6, then under conditions of ice-water bath, is added EDC and n-hydroxysuccinimide react 20-30 hours;Then, it is subsequently added into PB-CD-NH2, it is small that 20-30 is reacted at 25 DEG C When, solid product is separated and cleaned, PB-C-dots-CD is obtained;
Step 3, chloro- 2- nitre phenyl trifluoromethanesulfonate methane grafting polylysine (PLL (NF)) of synthesis NO donor 5-
Polylysine (PLL), potassium carbonate and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of 5- are dissolved in solvent DMF, 25 DEG C to 35 It flows back at DEG C back flow reaction three days 72-96 hours, sufficiently after dialysis, freeze-drying obtains PLL (NF);
Step 4, the Prussian blue (PB- of the chloro- 2- nitre phenyl trifluoromethanesulfonate methane grafting Mercapto-group modification of synthesis NO donor 5- C-dots-CD-PLL(NF))
PB-C-dots-CD and PLL (NF) are dispersed in the buffer solution that pH is 7.2~7.4, are stirred to react under room temperature 45-55 hours, solid product is separated, obtains PB-C-dots-CD-PLL (NF) after washing is dry;
Step 5 synthesizes Prussian blue (PB-C-dots-CD-PLL (the NF)-FA) of modified with folic acid
Folic acid is dissolved in the buffer solution that pH is 5-6, then under conditions of ice-water bath, 1- (3- diformazan ammonia is added Base propyl) after -3- ethyl-carbodiimide hydrochloride (EDC) and n-hydroxysuccinimide react 20-30 hours, add PB- C-dots-CD-PLL (NF) isolates solid product, as modified with folic acid is Prussian blue in room temperature reaction 20-30 hours (PB-C-dots-CD-PLL(NF)-FA)。
According to the above scheme, the Prussian blue prussian blue nano particle for citric acid surface modification, partial size is in 30nm- Within the scope of 200nm.
According to the above scheme, the excitation wavelength of carbon quantum dot is in 400nm-660nm.
According to the above scheme, in step 1, the Prussian blue concentration in buffer solution is within the scope of 1-2.5mg/mL.
According to the above scheme, in step 1,1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride, N- hydroxyl amber Concentration of the amber acid imide in buffer solution is 4-6mg/mL;EDA- β-CD, 2-aminoethyl disulfide dihydrochloride and Prussian blue mass ratio Respectively (6-9): (1-4): 10.
According to the above scheme, in step 2, concentration of the carbon quantum dot in buffer solution is within the scope of 1-20mg/ml.
According to the above scheme, in step 2, the concentration of EDC, n-hydroxysuccinimide in buffer solution is 15-30mg/ ml;PB-CD-NH2Mass ratio with carbon quantum dot is (1-10): 1.
According to the above scheme, in step 3, the mass ratio of potassium carbonate and PLL are 1:(1-3);PLL and the chloro- 2- nitre phenyl three of 5- The mass ratio of fluoromethane is 1:(0.5-4).
According to the above scheme, in step 4, the concentration range difference of PB-C-dots-CD and PLL (NF) in buffer solution is equal For 1-2mg/mL.
According to the above scheme, in step 5, folic acid is dissolved in the buffer solution that pH is 5-6, concentration 0.1-0.7mg/ml.
According to the above scheme, in step 5, the concentration of EDC, n-hydroxysuccinimide in buffer solution is 5-15mg/ ml;The mass ratio of PB-C-dots-CD-PLL (NF) and folic acid is 10:(0.5-3).
Compared with prior art, the beneficial effects of the present invention are:
Firstly, medicament carrier system provided by the invention, can be realized by folate-targeted and tumor locus EPR effect Effective enrichment of tumor locus, under near-infrared laser irradiation, prussian blue nano particle can pass through excellent photothermal conversion Efficiency ablated tumor cell.Meanwhile the medicament carrier system can control nitric oxide production release under the illumination of 400nm wavelength It puts, enhances nanoparticle in the enrichment of tumor locus so as to improve EPR effect, while NO can be inverse with inducing apoptosis of tumour cell Turn multidrug resistance etc. and inhibits tumour growth.
Second, NO donor is discharged by 400nm laser controlling in the medicament carrier system, will not be discharged, be can control in advance Its toxic side effect to normal cell;And the vasodilation that NO can be mediated, so that carrier is more enriched in tumor locus, simultaneously Mitigate the anoxic of tumor locus.
Third, it is Prussian blue can with carbon quantum dot formed fluorescent quenching, the carbon quantum that the present invention is grafted by cystine linkage Point is modified Prussian blue, and the GSH response in tumour, which may be implemented, causes fluorescent quenching to disappear, and realizes the fixed point prison of drug Depending on tracking carrier well in vivo, there is visual navigation.Since glutathion inside cell (GSH) concentration is extracellular 1000 times of GSH concentration in matrix, fluorescent quenching disappears in tumour cell, realizes fluorescent visual.
4th, polylysine has good biocompatibility, also has a large amount of unique film characters, can enhance cell pair High molecular absorption;Folic acid has good targeting, and absorption of the tumour cell to carrier can be enhanced.
By the design of above series of, the present invention can construct one kind and have " tumour causes targeting " ability, based on PLL (NF) then-FA/ β-CD/PB composite Nano medicament carrier system, the fluorescent visual in tumour cell apply exogenous stimulation Discharge nitric oxide and photo-thermal ablated tumor cell, it can be ensured that normal cell will not be hurt, compared to traditional load drug carrier, The system has target administration ability in more efficient cancer cell, can effectively improve utilization ratio of drug and reduces the secondary work of its poison With.
Detailed description of the invention
The TEM figure that Fig. 1 is prussian blue nano particle PB used by embodiment;
The TEM figure that Fig. 2 is carbon quantum dot C-dots used by embodiment;
Fig. 3 is used by embodiment in 1W/cm2, under 808nm laser irradiation various concentration prussian blue nano particle The photo-thermal figure of PB;
Fig. 4 is used by embodiment in 1W/cm2, 0.25mg/ml prussian blue nano particle under 808nm laser irradiation The solar thermochemical cycle figure of PB;
Fig. 5 is the nuclear-magnetism figure of PLL (NF) used by embodiment;
The NO release that Fig. 6 is PLL (NF) used by embodiment;
Fig. 7 is the infrared figure of Fourier of each step products in embodiment 1;
Fig. 8 is the thermogravimetric analysis figure of each step products in embodiment 1;
Fig. 9 is the fluorescence of 1 products therefrom GSH of embodiment before and after the processing;
Figure 10 is that the cell of nano-carrier used by embodiment 1 absorbs the relationship with the time;
Figure 11 is photo-thermal fragmentation effect of nano-carrier when 50ug/mL and 100ug/mL used by embodiment 1;
Figure 12 is the MTT toxicity detection of nano-carrier used by embodiment 1.
Specific embodiment
For a better understanding of the present invention, below with reference to the embodiment content that the present invention is furture elucidated, but the present invention is not It is limited only to the following examples.
PB, β-CD-OTs, EDA- β-CD, the C-dots being related in following embodiments can be prepared with the following method, It can also be prepared using other methods.
1, the synthesis (PB) of prussian blue nano particle
It is prepared for the prussian blue nano particle (PB NPs) of citric acid surface modification in the following way, it is specific to prepare Steps are as follows: by the FeCl of a certain amount3And K4[Fe(CN)6] it is added separately to the 20mL deionization containing 0.5mmol citric acid In water, make FeCl3And K4[Fe(CN)6] final concentration be 1.0mmol/L;Then by above-mentioned FeCl3Solution and K4[Fe(CN)6] Solution is separately heated to 60 DEG C, and by K4[Fe(CN)6] solution in 60 DEG C stirring under be added dropwise to FeCl3In solution;With dropwise addition It carries out, solution can gradually become blue, be cooled to room temperature after which is persistently continued stirring 30min.
The acetone isometric with above-mentioned blue solution is added thereto, 30min is placed at room temperature, then in 12500r/m Nanoparticle is collected after centrifugation 60min, and is washed repeatedly 3 times;The prussian blue nano particle of collection is finally set into vacuum drying In case, dry 12h, spare under the conditions of 50 DEG C.
2. (1) preparation (β-CD-OTs) of tolysulfonyl oxygen group-beta-cyclodextrin
It weighs 25g beta-cyclodextrin (β-CD) and is dissolved in the NaOH solution of 300mL 0.4M, stirred in ice-water bath It mixes until cyclodextrin is completely dissolved;The paratoluensulfonyl chloride (TsCl) of 18g is slowly added dropwise into aforementioned β-CD solution, in ice water After being stirred to react 90min in bath, then filter;Taken filtrate adjusts its pH to 8.5 with HCl, then continues to be stirred to react at room temperature 2 hours, products therefrom was placed in refrigerator (4 DEG C) one nights of placement, is filtered, filter residue is washed with deionized three times, at 60 DEG C After drying, β-CD-OTs is obtained.
(2) EDA- β-CD is synthesized
It weighs the β-CD-OTs 2.5g prepared and is added to ethylenediamine 15ml steams again after, dissolve it at normal temperature And logical nitrogen 30min or so, it places into and continues back flow reaction 48h under nitrogen protection in 80 DEG C of water-baths, then simultaneously with acetone precipitation It is filtered with organic filter membrane of 450nm, finally continues with acetone precipitation twice, to obtain yellowish white powder air drying with water dissolution 50h obtains the product EDA- β-CD of about 2.2g, and yield is about 95.7%
3. the synthesis (C-dots) of carbon quantum dot
It weighs 1.6g citric acid and 0.6g urea and is dissolved in the DMF of 10ml, then pour into the mixed solution It into 20mL polytetrafluoroethylene (PTFE) autoclave, is reacted 12 hours at 200 DEG C, is centrifuged off solid after reaction, on gained Clear liquid is cleaned three times with (petroleum ether: ethyl acetate=4:1) mixed liquor, and 12h is dried in vacuo at 70 DEG C can be obtained carbon quantum dot.
Prussian blue nano particle and carbon quantum dot are diluted to certain multiple, with its form of transmission electron microscope observing, such as Fig. 1 With shown in Fig. 2, carrier is the cube structure that partial size is about 45nm, and carbon quantum dot partial size is 3~4nm.
Fig. 3 is photo-thermal test of the prussian blue nano particle under various concentration, from the figure 3, it may be seen that prussian blue nano grain Son has good light thermal property.
Fig. 4 is that the photo and thermal stability of prussian blue nano particle is tested, and as shown in Figure 4, prussian blue nano particle has good Good photo and thermal stability, can be with Repeat-heating.
Fig. 5 is the nuclear-magnetism figure of PLL (NF), and as shown in Figure 7, the integral of PLL (NF), which compares, meets expection with chemical shift, shows The synthesis success of PLL (NF).
Fig. 6 is the release experiment of NO, and under 400nm illumination, NO largely discharges, and also demonstrates the synthesis of PLL (NF) and connects Branch success.
Embodiment 1
A kind of preparation method of composite Nano medicament carrier system, specifically comprises the following steps:
1. synthesizing PB-CD-NH2
It weighs PB 200mg to be dispersed in the PBS that the pH of 100ml is 5.5, then under the conditions of 4 DEG C of ice-water bath, EDC is added (1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride 2.87g and n-hydroxysuccinimide 1.7262g, reaction 24 Hour;It is subsequently added into 140mgEDA- β-CD and 60mg 2-aminoethyl disulfide dihydrochloride to react 24 hours, eccentric cleaning obtained solid product, As PB-CD-NH2
2. synthesizing PB-C-dots-CD
It weighs carbon quantum dot 60mg to be dispersed in the PBS that the pH of 100ml is 5.5, EDC then is added at 4 DEG C of ice-water bath 1.7262g and n-hydroxysuccinimide 2.87g simultaneously reacts 24 hours, adds 200mg PB-CD-NH2 room temperature reaction for 24 hours, Eccentric cleaning obtained solid product, as PB-C-dots-CD.
3. synthesizing PLL (NF)
200mg PLL, 100mg potassium carbonate and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane 200mg of 5- is weighed to flow back in 25mL DMF It three days, dialyses three days at room temperature, changes within every 6 hours a deionized water, freeze-drying obtains PLL (NF).
4. synthesizing PB-C-dots-CD-PLL (NF)
100mg PB-C-dots-CD and 100mgPLL (NF) are weighed, is dispersed in the PBS buffer solution of 60ml (pH7.4), it is stirred to react under room temperature two days, solid product is centrifuged out, cleaned for several times with deionized water, vacuum drying obtains Product PB-C-dots-CD-PLL (NF).
5. synthesizing PB-C-dots-CD-PLL (NF)-FA
It weighs folic acid 20mg to be dissolved in the PBS that the pH of 200ml is 5.5, then under the conditions of 4 DEG C of ice-water bath, EDC is added 1.7262g and n-hydroxysuccinimide 2.87g reacts 24 hours, adds 200mg PB-C-dots-CD-PLL (NF), room Temperature is reacted for 24 hours, eccentric cleaning obtained solid product, as PB-C-dots-CD-PLL (NF)-FA.
As shown in Figure 7, in above-mentioned steps, the stretching vibration peak of the specific groups of each step grafting it is observed that, show Every single step reaction is successful.In conjunction with Fig. 8 it is found that the TG of grafting carbon quantum dot rises, the TG after other each step grafting declines, Show the grafting success of nanoparticle.
Using test
1, influence of the GSH presence or absence to PB-C-dots-CD-PLL (NF)-FA: suitable PB-CD-C-dots-PLL is taken (NF) the PBS buffer solution that-FA is dispersed in pH=7.4 respectively neutralizes the PBS buffer solution of the pH=7.4 containing 10mM GSH In.It is placed in 37 degrees Celsius of shaking table 24 hours, is centrifuged, washing detects fluorescence.
As shown in Figure 9, PB-C-dots-CD-PLL (NF)-FA does not have fluorescence in the presence of no GSH, in the presence of GSH Fluorescence occurs, and shows the grafting success of nanoparticle.
2, it inquires into cell to absorb and co-culture the relationship between the time: by HeLa cell with 1.0 × 104Cells/well's Concentration kind enters in 6 orifice plates.After culture for 24 hours, the culture solution in original each orifice plate is substituted for the DMEM packet of fresh 1mL respectively Containing PB-CD-C-dots-PLL (NF)-FA, PB-CD-C-dots-PLL (NF) and PB-CD-C-dots-PLL-FA, with its institute Concentration containing PB is counted, and PB concentration is 100 μ g/mL-1.After cell incubation different time, PBS is washed three times, trypsinized, 5min is collected by centrifugation in 1100rpm, finally, being handled with concentrated nitric acid solution.Contained with ICP-MS (PerkinElmer company, the U.S.) test Iron.
As shown in Figure 10, when the 8th hour, cell is to the uptake highest of nano-carrier, and PB-CD-C- Dots-PLL (NF)-FA's and PB-CD-C-dots-PLL-FA is above PB-CD-C-dots-PLL (NF), can effectively demonstrate,prove The targeting of bright folic acid.
3, photo-thermal cytotoxicity experiment carries out photo-thermal effect evaluation using HeLa cell.By HeLa cell with 1.0 × 104The concentration kind of cells/well enters in 6 orifice plates, and 1mL is added in each orifice plate and contains 10%FBS and 1% antibiotic DMEM culture medium.It include PBS by the DMEM that the culture solution in original each orifice plate is substituted for fresh 1mL respectively after culture for 24 hours (control group), PB-CD-C-dots-PLL (NF)-FA, PB-CD-C-dots-PLL (NF) and PB-CD-C-dots-PLL-FA, In terms of the concentration of PB contained by it is come, net PB concentration maintains always 100 μ g/mL.After cultivating 24 hours, it is with power density 1w/cm-2808nm laser irradiation 5min after, continue culture for 24 hours.Cell is washed three times with PBS, with depositing for mtt assay measurement cell Motility rate.
As shown in Figure 11, control group is using 1W/cm2, under 808nm laser irradiation without obvious killing, it was demonstrated that laser photograph Biggish harm will not be had to cell by penetrating.And the fragmentation effect of PB-CD-C-dots-PLL (NF)-FA is best, PB-CD-C- The fragmentation effect of dots-PLL (NF) is secondly, the fragmentation effect of PB-CD-C-dots-PLL-FA is worst, the fragmentation effect of high concentration Higher than low concentration.Drug has good targeting according to Figure 10 and Figure 12, and drug itself is without the secondary work of biggish poison With.But drug NO can effectively discharge under light illumination, kill cell, and have good photo-thermal fragmentation effect.It demonstrates The system has target administration ability in more efficient cancer cell, can effectively improve utilization ratio of drug and reduces the secondary work of its poison With.
4, HeLa cell is inoculated in 96 orifice plates of 96 orifice plates with the density of 8000 cells/wells, culture for 24 hours, is added PB-CD-C-dots-PLL (NF)-FA, PB-CD-C-dots-PLL (NF) and PB-CD-C-dots-PLL-FA of various concentration with After cell co-cultures 48h, after culture, the fresh DMEM culture medium of 200 μ L and 20 μ L MTT solution will be changed in culture medium (5mg/mL PBS).Continue after cultivating 4h, MTT solution is carefully removed, adds 150 μ L DMSO into hole, culture medium pallet Concussion is rocked at room temperature, is uniformly mixed.The each hole (Model 550, Bio-Rad, USA) is recorded in microplate reader in 570nm Absorbance, cell survival rate calculation formula is as follows:
Wherein OD570(control)It is the light absorption value measured when material not being added, OD570(treated)It is measured after material is added Light absorption value.
As shown in Figure 12, the cell survival rate of the carrier system is above 90%, has good biocompatibility and nothing Obvious toxic-side effects.
Embodiment 2
A kind of preparation method of composite Nano medicament carrier system, specifically comprises the following steps:
1. synthesizing PB-CD-NH2
PB 200mg is weighed to be dispersed in 100ml deionized water, with salt acid for adjusting pH to 5-6 (if adjust be lower than 5, can A small amount of sodium hydroxide readjustment is added), then under the conditions of 4 DEG C of ice-water bath, EDC (1- (3- dimethylamino-propyl) -3- ethyl is added Carbodiimide hydrochloride 2.87g and n-hydroxysuccinimide 1.7262g reacts 24 hours;It is subsequently added into 140mgEDA- β-CD It is reacted 24 hours with 60mg 2-aminoethyl disulfide dihydrochloride, eccentric cleaning obtained solid product, as PB-CD-NH2.
2. synthesizing PB-C-dots-CD
It weighs carbon quantum dot 60mg to be dispersed in water, with salt acid for adjusting pH to 5-6, then be added at 4 DEG C of ice-water bath EDC1.7262g and n-hydroxysuccinimide 2.87g simultaneously reacts 24 hours, adds 200mg PB-CD-NH2 room temperature reaction For 24 hours, eccentric cleaning obtained solid product, as PB-C-dots-CD.
3. synthesizing PLL (NF)
200mg PLL, 100mg potassium carbonate and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane 200mg of 5- is weighed to flow back in 25mL DMF It three days, dialyses three days at room temperature, freeze-drying obtains PLL (NF).
4. synthesizing PB-C-dots-CD-PLL (NF)
100mg PB-C-dots-CD and 100mgPLL (NF) are weighed, is dispersed in the PBS buffer solution of 60ml (pH7.4), it is stirred to react under room temperature two days, solid product is centrifuged out, cleaned for several times with deionized water, vacuum drying obtains Product PB-C-dots-CD-PLL (NF).
5. synthesizing PB-C-dots-CD-PLL (NF)-FA
It weighs folic acid 20mg to be dissolved in 200ml water, adjusts PH to 5-6 with hydrochloric acid, then under the conditions of 4 DEG C of ice-water bath, add Enter EDC 1.7262g and n-hydroxysuccinimide 2.87g to react 24 hours, adds 200mg PB-C-dots-CD-PLL (NF), 48h, eccentric cleaning obtained solid product, as PB-C-dots-CD-PLL (NF)-FA are reacted at room temperature.
Embodiment 3
A kind of preparation method of composite Nano medicament carrier system, specifically comprises the following steps:
1. synthesizing PB-CD-NH2
It weighs PB 200mg to be dispersed in the PBS that the pH of 100ml is 5.5, then under the conditions of 4 DEG C of ice-water bath, EDC is added (1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride 2.87g and n-hydroxysuccinimide 1.7262g, reaction 24 Hour;It is subsequently added into 180mgEDA- β-CD and 20mg 2-aminoethyl disulfide dihydrochloride to react 24 hours, eccentric cleaning obtained solid product, As PB-CD-NH2
2. synthesizing PB-C-dots-CD
It weighs carbon quantum dot 60mg to be dispersed in the PBS that the pH of 100ml is 5.5, EDC then is added at 4 DEG C of ice-water bath 1.7262g and n-hydroxysuccinimide 2.87g simultaneously reacts 24 hours, adds 200mg PB-CD-NH2 room temperature reaction for 24 hours, Eccentric cleaning obtained solid product, as PB-C-dots-CD.
3. synthesizing PLL (NF)
200mg PLL, 100mg potassium carbonate and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane 600mg of 5- is weighed to flow back in 25mL DMF It three days, dialyses three days at room temperature, freeze-drying obtains PLL (NF).
4.PB-C-dots-CD-PLL(NF)
100mg PB-C-dots-CD and 100mgPLL (NF) are weighed, is dispersed in the PBS buffer solution of 60ml (pH7.4), it is stirred to react under room temperature two days, solid product is centrifuged out, cleaned for several times with deionized water, vacuum drying obtains Product PB-C-dots-CD-PLL (NF).
5. synthesizing PB-C-dots-CD-PLL (NF)-FA
It weighs folic acid 20mg to be dissolved in the PBS that the pH of 200ml is 5.5, then under the conditions of 4 DEG C of ice-water bath, EDC is added 1.7262g and n-hydroxysuccinimide 2.87g reacts 24 hours, adds 200mg PB-C-dots-CD-PLL (NF), room Temperature is reacted for 24 hours, eccentric cleaning obtained solid product, as PB-C-dots-CD-PLL (NF)-FA.
The detection method of each intermediate product and final product obtained by embodiment 2-3 is same as Example 1, it is verified at Medicament carrier system is made in function, has good targeting, and itself without biggish toxic side effect, NO can be effective under light illumination Release, kill cell, and have good photo-thermal fragmentation effect.The medicament carrier system of the present invention is demonstrated to have more Add target administration ability in efficient cancer cell, can effectively improve utilization ratio of drug and reduces its toxic side effect.
The above is only a preferred embodiment of the present invention, it is noted that come for those of ordinary skill in the art It says, without departing from the concept of the premise of the invention, several modifications and variations can also be made, these belong to of the invention Protection scope.

Claims (10)

1. a kind of medicament carrier system for having target administration ability in cancer cell, it is characterised in that it is with carbon quantum dot and β It is cyclodextrin modified it is Prussian blue be matrix, by being grafted in conjunction with polylysine with the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of NO donor 5- Afterwards, then obtained from modified with folic acid.
2. the preparation method described in claim 1 for having the medicament carrier system of target administration ability in cancer cell, feature It is mainly to include the following steps:
Step 1 synthesizes the Prussian blue PB-CD-NH of beta cyclodextrin and 2-aminoethyl disulfide dihydrochloride modification2
Prussian blue PB is dispersed in the aqueous solution that pH is 5-6, then under conditions of ice-water bath, EDC and N- hydroxyl is added Succinimide reacts 20-30 hours;Then, tolysulfonyl oxygen group-beta-cyclodextrin and 2-aminoethyl disulfide dihydrochloride room are subsequently added into Temperature reaction 20-30 hours, separates and cleans solid product, obtain PB-CD-NH2
Step 2, the Prussian blue PB-C-dots-CD of synthesis carbon quantum dot modification
Carbon quantum dot C-dots is dispersed in the aqueous solution that pH is 5-6, then under conditions of ice-water bath, EDC and N- is added HOSu NHS reacts 20-30 hours;Then, it is subsequently added into PB-CD-NH2, react 20-30 hours, separate at 25 DEG C And solid product is cleaned, obtain PB-C-dots-CD;
Step 3, chloro- 2- nitre phenyl trifluoromethanesulfonate methane grafting polylysine PLL (NF) of synthesis NO donor 5-
Polylysine PLL, potassium carbonate and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of 5- are dissolved in solvent DMF, flowed back at 25-35 DEG C Reaction 72-96 hours, sufficiently after dialysis, freeze-drying obtains PLL (NF);
Step 4, the Prussian blue PB-C- of the chloro- 2- nitre phenyl trifluoromethanesulfonate methane grafting Mercapto-group modification of synthesis NO donor 5- dots-CD-PLL(NF)
PB-C-dots-CD and PLL (NF) are dispersed in the buffer solution that pH is 7.2-7.4, are stirred to react 45-55 under room temperature Hour, solid product is separated, obtains PB-C-dots-CD-PLL (NF) after washing is dry;
Step 5 synthesizes Prussian blue PB-C-dots-CD-PLL (NF)-FA of modified with folic acid
Folic acid is dissolved in the aqueous solution that pH is 5-6, then under conditions of ice-water bath, EDC and N- hydroxysuccinimidyl acyl is added After imine reaction 20-30 hours, PB-C-dots-CD-PLL (NF) is added in room temperature reaction 20-30 hours, isolates solid Product, as PB-C-dots-CD-PLL (NF)-FA.
3. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 1, the Prussian blue prussian blue nano particle for citric acid surface modification, partial size is in 30nm-200nm In range;In step 2, the excitation wavelength of carbon quantum dot is in 400nm-660nm.
4. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 1, Prussian blue concentration in aqueous solution is within the scope of 1-2.5mg/mL;1- (3- dimethylamino third Base) -3- ethyl-carbodiimide hydrochloride, the concentration of n-hydroxysuccinimide in aqueous solution is 15-30mg/mL;EDA- β-CD, 2-aminoethyl disulfide dihydrochloride and Prussian blue mass ratio are respectively (6-9): (1-4): 10.
5. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 2, the concentration of carbon quantum dot in aqueous solution is within the scope of 1-20mg/ml;EDC, N- hydroxysuccinimidyl acyl are sub- Concentration of the amine in buffer solution is 15-30mg/ml;PB-CD-NH2Mass ratio with carbon quantum dot is (1-10): 1.
6. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 3, the mass ratio of potassium carbonate and PLL are 1:(1-3);The matter of PLL and the chloro- 2- nitre phenyl trifluoromethanesulfonate methane of 5- Amount is than being 1:(0.5-4).
7. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 4, the concentration range of PB-C-dots-CD and PLL (NF) in buffer solution is 1-2mg/mL respectively.
8. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 5, folic acid is dissolved in the aqueous solution that pH is 5-6, concentration 0.1-0.7mg/ml.
9. the preparation method according to claim 2 for having the medicament carrier system of target administration ability in cancer cell, It is characterized in that in step 5, the concentration of EDC, n-hydroxysuccinimide in buffer solution is 5-15g/ml;PB-C- The mass ratio of dots-CD-PLL (NF) and folic acid is 10:(0.5-3).
10. the pharmaceutical carrier for having target administration ability in cancer cell of any one of claim 2-9 the method preparation System.
CN201910563157.8A 2019-06-26 2019-06-26 Drug carrier system with cancer cell internal target administration capability and preparation method thereof Active CN110152021B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910563157.8A CN110152021B (en) 2019-06-26 2019-06-26 Drug carrier system with cancer cell internal target administration capability and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910563157.8A CN110152021B (en) 2019-06-26 2019-06-26 Drug carrier system with cancer cell internal target administration capability and preparation method thereof

Publications (2)

Publication Number Publication Date
CN110152021A true CN110152021A (en) 2019-08-23
CN110152021B CN110152021B (en) 2021-07-06

Family

ID=67636722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910563157.8A Active CN110152021B (en) 2019-06-26 2019-06-26 Drug carrier system with cancer cell internal target administration capability and preparation method thereof

Country Status (1)

Country Link
CN (1) CN110152021B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110639019A (en) * 2019-09-20 2020-01-03 湖北大学 Drug carrier system based on carbon dot and hollow manganese dioxide fluorescence resonance energy transfer
WO2022150763A1 (en) * 2021-01-11 2022-07-14 The George Washington University Nanoparticle-mediated immune cell manufacture and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120905A2 (en) * 2009-04-15 2010-10-21 Board Of Trustees Of Michigan State University Novel nano-probes for molecular imaging and targeted therapy of diseases
US20140271487A1 (en) * 2013-03-15 2014-09-18 Children's National Medical Center Prussian blue-inspired constructs for multimodal imaging and therapy
CN107375239A (en) * 2017-07-11 2017-11-24 湖北大学 A kind of composite Nano medicament carrier system for possessing tumour initiation targeting ability and preparation method thereof
CN108421047A (en) * 2018-03-31 2018-08-21 湖北大学 A kind of composite Nano medicament carrier system for having tumour and causing targeting ability
CN108785673A (en) * 2018-07-06 2018-11-13 重庆医科大学 A kind of Prussian blue similar object nanometer photo-thermal therapy agent of load medicine and preparation method thereof that sodium nitroprussiate is conjugated
CN109260175A (en) * 2018-10-17 2019-01-25 湖北大学 A kind of drug carrier controlled release system and preparation method thereof causing targeting ability with tumour
CN109289052A (en) * 2018-12-04 2019-02-01 华东理工大学 Nitric oxide and cis-platinum targeting joint controllable drug delivery Nano medication system and preparation
CN109486484A (en) * 2017-09-12 2019-03-19 首都医科大学 A kind of carbon dots/Prussian blue composite Nano system preparation and application having both green fluorescence and photothermal conversion efficiency

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120905A2 (en) * 2009-04-15 2010-10-21 Board Of Trustees Of Michigan State University Novel nano-probes for molecular imaging and targeted therapy of diseases
US20140271487A1 (en) * 2013-03-15 2014-09-18 Children's National Medical Center Prussian blue-inspired constructs for multimodal imaging and therapy
CN107375239A (en) * 2017-07-11 2017-11-24 湖北大学 A kind of composite Nano medicament carrier system for possessing tumour initiation targeting ability and preparation method thereof
CN109486484A (en) * 2017-09-12 2019-03-19 首都医科大学 A kind of carbon dots/Prussian blue composite Nano system preparation and application having both green fluorescence and photothermal conversion efficiency
CN108421047A (en) * 2018-03-31 2018-08-21 湖北大学 A kind of composite Nano medicament carrier system for having tumour and causing targeting ability
CN108785673A (en) * 2018-07-06 2018-11-13 重庆医科大学 A kind of Prussian blue similar object nanometer photo-thermal therapy agent of load medicine and preparation method thereof that sodium nitroprussiate is conjugated
CN109260175A (en) * 2018-10-17 2019-01-25 湖北大学 A kind of drug carrier controlled release system and preparation method thereof causing targeting ability with tumour
CN109289052A (en) * 2018-12-04 2019-02-01 华东理工大学 Nitric oxide and cis-platinum targeting joint controllable drug delivery Nano medication system and preparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
QIN GAO ET AL: ""Functionalized MoS2 Nanovehicle with Near-Infrared Laser-Mediated Nitric Oxide Release and Photothermal Activities for Advanced Bacteria-Infected Wound Therapy"", 《SMALL》 *
SHU-WEN SHI ET AL: ""Targeted and NIR light-controlled delivery of nitric oxide combined with a platinum(IV) prodrug for enhanced anticancer therapy"", 《J. MATER. CHEM. B》 *
YAN-HUI LI ET AL: ""A ruthenium-nitrosyl-functionalized nanoplatform for the targeting of liver cancer cells and NIR-light-controlled delivery of nitric oxide combined with photothermal therapy"", 《J. MATER. CHEM. B》 *
殷姝君 等: ""一种阿霉素/NO 供体光敏纳米复合物的合成与性质研究"", 《化学研究》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110639019A (en) * 2019-09-20 2020-01-03 湖北大学 Drug carrier system based on carbon dot and hollow manganese dioxide fluorescence resonance energy transfer
CN110639019B (en) * 2019-09-20 2022-10-11 湖北大学 Drug carrier system based on carbon dot and hollow manganese dioxide fluorescence resonance energy transfer
WO2022150763A1 (en) * 2021-01-11 2022-07-14 The George Washington University Nanoparticle-mediated immune cell manufacture and uses thereof

Also Published As

Publication number Publication date
CN110152021B (en) 2021-07-06

Similar Documents

Publication Publication Date Title
Li et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy
CN104353075B (en) A kind of water-soluble magnetic titanium dioxide and preparation method and application
CN108273059B (en) Preparation method and application of composite nano material for treating tumors by combining photo-thermal treatment and active oxygen treatment
CN105535972B (en) A kind of C3N4Nanocomposite, preparation method and applications
CN109503455B (en) Nano composite material using tetraphenyl ethylene indole derivative as photosensitizer, preparation method and application in tumor treatment
CN110152021A (en) A kind of medicament carrier system and preparation method thereof having target administration ability in cancer cell
CN105816877A (en) Preparation method of nanoparticles with photothermal effect and application thereof
CN110215438B (en) Preparation method and application of mesoporous silicon nanoparticles carrying anthracyclines and photosensitizers
CN112451680B (en) ROS sensitive nano reagent with synergistic induction of photodynamic therapy and iron death and preparation method thereof
WO2021114909A1 (en) Photodynamic therapy system, preparation method therefor, and use thereof in photodynamic therapy
CN106177948A (en) A kind of preparation method of the hollow silicon Venus core shell nano material wrapping up amycin
CN110368501B (en) RGD peptide modified boron drug-loading system and preparation and application thereof
CN105085710B (en) Sulfamide groups phenyl porphyrin hyaluronic acid polymer and its preparation method and application
CN111166882B (en) Phthalocyanine-RGD polypeptide-graphene oxide composite nano material and preparation method and application thereof
CN113797334A (en) Artemisinin & indocyanine green/ultrathin hydrotalcite nanosheet composite material and preparation and application thereof
CN111514293A (en) Application of near-infrared heavy-atom-free BODIPY in photodynamic therapy of metastatic tumor and up-conversion
CN113087877B (en) Near-infrared two-region fluorescence emission water-soluble conjugated polymer nano phototherapy reagent and preparation method and application thereof
CN113694023B (en) Oxidation response type nano micelle and preparation method and application thereof
CN112933229B (en) Carrier-free self-assembly nanoparticle of IR820 and atovaquone and preparation method and application thereof
CN111053901B (en) Sound sensitive agent with aggregation-induced emission characteristic and preparation method thereof
CN110841073B (en) Preparation method of MS2 protein nanoparticle coupled monocarboxyl zinc phthalocyanine and application of MS2 protein nanoparticle coupled monocarboxyl zinc phthalocyanine in resisting breast cancer
CN110734762B (en) Near-infrared photosensitizer and preparation method and application thereof
Kang et al. Applications of nanocomposites based on zeolitic imidazolate framework-8 in photodynamic and synergistic anti-tumor therapy
CN112870356B (en) Series of medicines for photodynamic therapy of tumor and application thereof
CN113230419A (en) Novel targeted nano-particles based on phycocyanobilin and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant